Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5960877 | 0.65 | — | — | |
| SCHEMBL7385000 | 0.59 | CYP2C19 (0.32) | CYP2C19HSD17B10AKR1B1 | |
| SCHEMBL29414131 | 0.56 | AKR1B1 (0.39) | CYP2C19HSD17B10AKR1B1 | |
| SCHEMBL9168700 | 0.55 | KDM4E (0.33) | HSD17B10AKR1B1 | |
| SCHEMBL8924542 | 0.53 | ALDH1A1 (0.33) | CYP2C19HSD17B10AKR1B1 | |
| SCHEMBL8487479 | 0.52 | AKR1B1 (0.48) | HSD17B10AKR1B1 | |
| SCHEMBL30910833 | 0.52 | — | — | |
| SCHEMBL29048386 | 0.51 | AKR1B1 (0.52) | HSD17B10AKR1B1 | |
| SCHEMBL69614 | 0.51 | CA2 (0.79) | HSD17B10AKR1B1 | |
| SCHEMBL583915 | 0.51 | AKR1B1 (0.60) | HSD17B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751095-B1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2021-10-27 | — | — | EP | disclosed |
| US-9193710-B2 | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150025064-A1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-22 | — | — | US | disclosed |
| EP-2751095-A2 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | Sanford-Burnham Medical Research Institute (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033246-A2 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | BRAINCELLS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025064-A1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | GRM1, GRM3, GRM2 | CYP2C19 579/4885HSD17B10 2332/4885AKR1B1 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.